1. Home
  2. LGND vs SBLK Comparison

LGND vs SBLK Comparison

Compare LGND & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • SBLK
  • Stock Information
  • Founded
  • LGND 1987
  • SBLK 2006
  • Country
  • LGND United States
  • SBLK Greece
  • Employees
  • LGND N/A
  • SBLK N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • SBLK Marine Transportation
  • Sector
  • LGND Health Care
  • SBLK Consumer Discretionary
  • Exchange
  • LGND Nasdaq
  • SBLK Nasdaq
  • Market Cap
  • LGND 2.0B
  • SBLK 1.9B
  • IPO Year
  • LGND 1992
  • SBLK N/A
  • Fundamental
  • Price
  • LGND $102.19
  • SBLK $16.51
  • Analyst Decision
  • LGND Strong Buy
  • SBLK Strong Buy
  • Analyst Count
  • LGND 8
  • SBLK 3
  • Target Price
  • LGND $144.71
  • SBLK $22.67
  • AVG Volume (30 Days)
  • LGND 118.3K
  • SBLK 1.2M
  • Earning Date
  • LGND 05-08-2025
  • SBLK 05-14-2025
  • Dividend Yield
  • LGND N/A
  • SBLK 8.72%
  • EPS Growth
  • LGND N/A
  • SBLK N/A
  • EPS
  • LGND N/A
  • SBLK 1.96
  • Revenue
  • LGND $181,488,000.00
  • SBLK $1,236,718,000.00
  • Revenue This Year
  • LGND $17.68
  • SBLK N/A
  • Revenue Next Year
  • LGND $18.69
  • SBLK $17.42
  • P/E Ratio
  • LGND N/A
  • SBLK $8.40
  • Revenue Growth
  • LGND 53.40
  • SBLK 25.60
  • 52 Week Low
  • LGND $77.43
  • SBLK $12.06
  • 52 Week High
  • LGND $129.90
  • SBLK $27.39
  • Technical
  • Relative Strength Index (RSI)
  • LGND 44.63
  • SBLK 62.67
  • Support Level
  • LGND $98.90
  • SBLK $15.82
  • Resistance Level
  • LGND $103.17
  • SBLK $16.35
  • Average True Range (ATR)
  • LGND 3.05
  • SBLK 0.40
  • MACD
  • LGND -0.27
  • SBLK -0.01
  • Stochastic Oscillator
  • LGND 31.94
  • SBLK 55.30

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About SBLK Star Bulk Carriers Corp.

Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.

Share on Social Networks: